

US EPA ARCHIVE DOCUMENT



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY  
WASHINGTON, D.C. 20460

*reading  
reviewer*

AUG 25 1987

OFFICE OF  
PESTICIDES AND TOXIC SUBSTANCES

MEMORANDUM

Subject: Chronic Dog Feeding Study on a Major Metabolite of Atrazine -  
FIFRA Section 6(a)(2) Data. Submitted by Ciba-Geigy Corporation  
August 4, 1987. Record No.: 201148.  
Tox. Branch Projecr No. 7-0890. Tox. Chem. No. 63

To: Robert Taylor  
Product Manager #25  
Registration Division (TS-767C)

From: Judith W. Hauswirth, Ph.D. *Judith W. Hauswirth*  
Section Head, Section VI *8/21/87*  
Toxicology Branch/HED (TS-769C)

Thru: Theodore M. Farber, Ph.D., Chief *TMF WTS*  
Toxicology Branch/HED (TS-769C) *8/25/87*

Ciba-Geigy has submitted this letter in accordance with the EPA's proposed Interpretive Rule on Section 6(a)(2) of FIFRA (Reporting of Adverse Effects). They are in the process of conducting a chronic dog feeding study on a major metabolite of atrazine, namely 6-chloro-2,4-diamino-s-triazine. Levels of the metabolite being tested in this study are 0, 5, 100 and 1500 ppm in the diet. At the end of five weeks of feeding, 4 out of 20 dogs in the high dose group (1500 ppm) have showed atrial fibrillation. Two of these dogs are also showing pre-cordial thrill.

Ciba-Geigy has stated that they will do the following with regards to this finding:

1. Lower the highest dose level in the dog study from 1500 ppm to 1000 ppm;
2. After 13 weeks on study, remove two dogs from the high dose feeding group and place them on control diet as a recovery group; and
3. Provide the Agency with a full copy of the final report when they receive it.

Toxicology Branch has no objection to what Ciba-Geigy has outlined above in response to the adverse affects they are seeing in this study. We have one obvious comment which is that the two dogs placed on control diet for a recovery group also be dogs that have been noted to have had atrial fibrillation. We also hope that Ciba-Geigy will keep us informed on the progress of this study so that further changes could be made as deemed necessary, i.e. further lowering of the high dose level.

Ciba-Geigy also notes that atrial fibrillation was seen in the chronic one-year dog feeding study on atrazine and that this study was initiated to expand the data base on atrazine since 6-chloro-2,4-diamino-s-triazine is a major metabolite of atrazine.